O2PC34 Stock Overview
Option Care Health, Inc. offers home and alternate site infusion services in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Option Care Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$39.67 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 1.32 |
| 1 Month Change | -5.75% |
| 3 Month Change | 13.64% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| O2PC34 | BR Healthcare | BR Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | 0.4% |
| 1Y | n/a | 0.9% | 14.6% |
Return vs Industry: Insufficient data to determine how O2PC34 performed against the BR Healthcare industry.
Return vs Market: Insufficient data to determine how O2PC34 performed against the BR Market.
Price Volatility
| O2PC34 volatility | |
|---|---|
| O2PC34 Average Weekly Movement | 3.2% |
| Healthcare Industry Average Movement | 6.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 8.9% |
| 10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: O2PC34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine O2PC34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 6,828 | John Rademacher | www.optioncarehealth.com |
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including Crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and others; infusion therapies for bleeding disorders; therapies that women need to survive and thrive through high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services.
Option Care Health, Inc. Fundamentals Summary
| O2PC34 fundamental statistics | |
|---|---|
| Market cap | R$27.23b |
| Earnings (TTM) | R$1.27b |
| Revenue (TTM) | R$20.69b |
21.8x
P/E Ratio1.3x
P/S RatioIs O2PC34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| O2PC34 income statement (TTM) | |
|---|---|
| Revenue | US$4.21b |
| Cost of Revenue | US$3.24b |
| Gross Profit | US$965.18m |
| Other Expenses | US$707.74m |
| Earnings | US$257.44m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Feb 22, 2024
| Earnings per share (EPS) | 1.45 |
| Gross Margin | 22.95% |
| Net Profit Margin | 6.12% |
| Debt/Equity Ratio | 73.8% |
How did O2PC34 perform over the long term?
See historical performance and comparison